These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29188799)

  • 1. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.
    Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
    Acta Pharmacol Sin; 2018 Jan; 39(1):154-164. PubMed ID: 29188799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.
    Zhao Z; Huang T; Li J
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
    Mafi A; Kim SK; Goddard WA
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.
    Chen XT; Pitis P; Liu G; Yuan C; Gotchev D; Cowan CL; Rominger DH; Koblish M; Dewire SM; Crombie AL; Violin JD; Yamashita DS
    J Med Chem; 2013 Oct; 56(20):8019-31. PubMed ID: 24063433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
    Yudin Y; Rohacs T
    Br J Pharmacol; 2019 Sep; 176(17):3110-3125. PubMed ID: 31074038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
    Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
    Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
    Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
    Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies.
    Miyano K; Manabe S; Komatsu A; Fujii Y; Mizobuchi Y; Uezono E; Ohshima K; Nonaka M; Kuroda Y; Narita M; Uezono Y
    Curr Top Med Chem; 2020; 20(31):2822-2829. PubMed ID: 33115393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways.
    Schneider S; Provasi D; Filizola M
    Biochemistry; 2016 Nov; 55(46):6456-6466. PubMed ID: 27778501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation.
    Liao S; Tan K; Floyd C; Bong D; Pino MJ; Wu C
    Life Sci; 2021 Mar; 269():119026. PubMed ID: 33444617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular basis of agonist/antagonist mechanism of human mu opioid receptor through gaussian accelerated molecular dynamics method.
    Wang YT; Chan YH
    Sci Rep; 2017 Aug; 7(1):7828. PubMed ID: 28798303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
    Austin Zamarripa C; Edwards SR; Qureshi HN; Yi JN; Blough BE; Freeman KB
    Drug Alcohol Depend; 2018 Nov; 192():158-162. PubMed ID: 30261403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand based conformational space studies of the μ-opioid receptor.
    Sena DM; Cong X; Giorgetti A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129838. PubMed ID: 33373630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring biased activation characteristics by molecular dynamics simulation and machine learning for the μ-opioid receptor.
    Chen J; Gou Q; Chen X; Song Y; Zhang F; Pu X
    Phys Chem Chem Phys; 2024 Apr; 26(14):10698-10710. PubMed ID: 38512140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
    Jiang X; Li S; Zhang H; Wang LL
    Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
    Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
    Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noribogaine is a G-protein biased κ-opioid receptor agonist.
    Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
    Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
    DeWire SM; Yamashita DS; Rominger DH; Liu G; Cowan CL; Graczyk TM; Chen XT; Pitis PM; Gotchev D; Yuan C; Koblish M; Lark MW; Violin JD
    J Pharmacol Exp Ther; 2013 Mar; 344(3):708-17. PubMed ID: 23300227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights into µ-opioid receptor activation.
    Huang W; Manglik A; Venkatakrishnan AJ; Laeremans T; Feinberg EN; Sanborn AL; Kato HE; Livingston KE; Thorsen TS; Kling RC; Granier S; Gmeiner P; Husbands SM; Traynor JR; Weis WI; Steyaert J; Dror RO; Kobilka BK
    Nature; 2015 Aug; 524(7565):315-21. PubMed ID: 26245379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.